Vol. 5 No. 12 (2025)
Reimbursement Recommendations

Fecal Microbiota (Rebyota)

decorative image of the issue cover

Published December 1, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Rebyota be reimbursed by public drug plans for the prevention of recurrence of Clostridioides difficile infection (CDI) in adults if certain conditions are met.
  • Rebyota should only be covered for adult patients who have experienced 2 or more recurrences of CDI despite appropriate antibiotic treatment for previous episodes. Rebyota is administered after completing antibiotic therapy for the current CDI recurrence.
  • Rebyota should only be reimbursed if prescribed and administered by doctors and care teams who are experienced in treating repeat CDI and in using this type of treatment, and if the cost of Rebyota is reduced. Rebyota should only be reimbursed as 1 dose. If CDI comes back after that first dose, patients may be able to get another dose for each recurrence, if the original initiation criteria are met.